Ovarian Cancer Treatment: Surgery, Chemotherapy, PARP Inhibitors and Modern Oncology Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Ovarian cancer is the fifth leading cause of cancer death in women in high-income countries and the most lethal gynaecological malignancy, largely because most cases present at advanced stage when symptoms are non-specific. Approximately 313,000 new cases and 207,000 deaths occur globally each year (GLOBOCAN 2022). In the UK, ~7,500 women are diagnosed annually; in the US, ~19,800 cases with ~12,400 deaths are reported yearly (SEER 2024).

The vast majority (~90%) of ovarian cancers are epithelial ovarian carcinomas (EOC). High-grade serous carcinoma (HGSC) is the most common histological subtype (~70% of EOC), characterised by near-universal TP53 mutations, frequent BRCA1/2 alterations (germline and somatic), and homologous recombination deficiency (HRD). Other EOC subtypes include low-grade serous, endometrioid, clear cell, and mucinous carcinomas, each with distinct genomic profiles, chemotherapy sensitivities, and clinical behaviours. Non-epithelial tumours (germ cell and sex cord-stromal tumours) represent ~10% and have very different treatment approaches.

FIGO 2023 staging remains the backbone of treatment planning. Stage I is confined to ovaries (5-year survival ~90%); stage II involves pelvic extension (~70%); stage III has peritoneal spread within the abdomen or retroperitoneal lymph nodes (~40%); stage IV has distant metastases beyond the peritoneal cavity (~29%). Approximately 75% of cases are diagnosed at stage III or IV, explaining the historically poor overall prognosis. Despite this, major advances in surgical technique (optimal cytoreduction), platinum-based chemotherapy, targeted maintenance therapy (PARP inhibitors, bevacizumab), and molecularly directed treatments have significantly improved outcomes over the past decade.

Treatment in ovarian cancer is highly subtype- and stage-specific. Understanding the histological and molecular landscape is essential for selecting appropriate therapy:

High-Grade Serous Carcinoma (HGSC)

The most common and most studied subtype. HGSC is characterised by TP53 mutation (~96%), frequent BRCA1/2 alterations (~20–25% germline, ~5–7% somatic), and HRD (~50% of tumours). This subtype is highly platinum-sensitive at first diagnosis, making carboplatin-based chemotherapy the cornerstone of treatment. PARP inhibitor maintenance therapy provides the greatest benefit in BRCA-mutated and HRD-positive HGSC.

Low-Grade Serous Carcinoma (LGSC)

A distinct entity from HGSC, driven by RAS/RAF/MEK pathway activation (KRAS/BRAF/NRAS mutations ~30%). LGSC is relatively chemotherapy-resistant; MEK inhibitors (trametinib — GOG-281/LOGS trial) have shown activity as second-line therapy. Endocrine therapy (aromatase inhibitors) also has activity in ER-positive LGSC.

Clear Cell Carcinoma

Associated with endometriosis; more common in Asian women (~25% of EOC in Japan vs ~5% in Western populations). High rates of ARID1A mutations and PIK3CA mutations. Often platinum-resistant even at first presentation; clinical trial enrolment is strongly encouraged at all stages. Immune checkpoint inhibitors may have activity in mismatch repair-deficient clear cell carcinoma.

Endometrioid Carcinoma

Often associated with Lynch syndrome (MMR deficiency in ~10–15%). Typically diagnosed at earlier stage; generally platinum-sensitive. CTNNB1 (beta-catenin) and PTEN mutations are characteristic.

Mucinous Carcinoma

Rare primary ovarian mucinous carcinomas (<3% of EOC) are often early stage and treated with primary surgery. Most mucinous ovarian tumours at advanced stage are metastatic (e.g., from colorectal/appendiceal primary). Primary mucinous EOC at advanced stages is generally platinum-resistant; FOLFOX or other gastrointestinal chemotherapy regimens may be appropriate.

Germ Cell and Sex Cord-Stromal Tumours

Occur most commonly in younger women. Germ cell tumours (dysgerminoma, immature teratoma) are highly chemosensitive (BEP — bleomycin, etoposide, cisplatin). Granulosa cell tumours are the most common sex cord-stromal tumours; inhibin B is a useful biomarker. Fertility-sparing surgery is often feasible in these non-epithelial histologies.

Eligibility for specific treatments in ovarian cancer is determined by a combination of surgical resectability, histological subtype, biomarker status, and performance status. A multidisciplinary gynaecological oncology team review is mandatory before initiating any treatment:

Surgical Eligibility — Primary Debulking Surgery (PDS): Assessment by an experienced gynaecological oncologist is essential. Laparoscopic staging (Fagotti score; predictive index score ≥8 identifies irresectable disease) or CT-based predictive models help triage patients to PDS vs neoadjuvant chemotherapy (NACT). The EORTC 55971 trial established that NACT + interval debulking surgery (IDS) is non-inferior to PDS for stage IIIc/IV disease with high predicted surgical risk; this approach is preferred when complete resection is not achievable at initial surgery.

BRCA1/2 Germline Testing: Recommended for all patients with newly diagnosed EOC regardless of family history (NCCN/ESMO 2024). Germline BRCA1/2 pathogenic variants are present in ~15–20% of HGSC and guide eligibility for olaparib maintenance (SOLO-1: HR 0.30 in BRCA-mutated first-line remission) and platinum-sensitive relapse treatment.

Tumour HRD Testing: Myriad myChoice CDx assay (FDA-approved companion diagnostic) measures genomic instability (genomic scar) as a proxy for HRD. HRD-positive tumours (BRCA-mutated or BRCA wild-type with high genomic instability) derive greater benefit from niraparib (PRIMA trial: PFS 13.8 vs 8.2 months in HRD-positive patients) and olaparib + bevacizumab (PAOLA-1). Required before initiating niraparib maintenance in first-line remission.

Lynch Syndrome Screening: MMR IHC on tumour tissue is recommended for all newly diagnosed ovarian cancer (ESMO/ESGO 2022 guidelines). Germline testing of MLH1, MSH2, MSH6, and PMS2 is indicated for MMR-deficient tumours; Lynch syndrome is identified in ~10–15% of endometrioid and clear cell carcinomas.

Performance Status and Organ Function: Adequate renal function (GFR ≥30 mL/min for carboplatin; ≥51 mL/min for cisplatin-based HIPEC), ECOG 0–2, and recovery from surgical debulking are required before initiating chemotherapy. PARP inhibitors require adequate haematological function (Hb ≥10 g/dL, platelets ≥100 × 10⁹/L, ANC ≥1.5 × 10⁹/L) at initiation.

Primary Debulking Surgery (PDS): Complete cytoreduction to no visible residual disease (R0) is the single strongest independent prognostic factor in advanced EOC. Operations are performed by subspecialty-trained gynaecological oncologists and may include total peritonectomy, bowel resection, diaphragmatic stripping, liver resection, and splenectomy. The AGO DESKTOP III and SOLO-1 subgroup analyses confirm that R0 resection confers a 2–3 fold OS advantage over residual disease. Minimally invasive staging laparoscopy is standard for stage I–IIA disease.

Neoadjuvant Chemotherapy (NACT) + Interval Debulking Surgery (IDS): For stage IIIc/IV patients where R0 is not predicted at primary surgery, NACT followed by IDS at 3–4 cycles achieves equivalent OS to upfront PDS (EORTC 55971: OS 29 vs 30 months; CHORUS trial: OS 24.1 vs 22.6 months). IDS R0 rates are higher after NACT (~51% vs 41%). Standard NACT is carboplatin + paclitaxel × 3–4 cycles; bevacizumab may be added as discussed below.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Van Driel et al. (NEJM 2018) demonstrated that HIPEC with cisplatin 100 mg/m² at the time of IDS improved median OS from 33.9 to 45.7 months (HR 0.67) in stage III EOC. HIPEC is now offered at specialist centres in the Netherlands and internationally as a component of IDS for stage III disease. It is not yet universally adopted; GOG-252 (comparing IP cisplatin vs IV + bevacizumab) found IP cisplatin was not superior to IV + bevacizumab.

Standard Chemotherapy: Carboplatin AUC 5–6 + paclitaxel 175 mg/m² IV every 3 weeks × 6 cycles remains the global first-line standard for EOC. Weekly dose-dense paclitaxel (ICON8/JGOG3016) showed PFS benefit in Japanese populations but was not confirmed in the ICON8 European trial. Dose-dense IP chemotherapy is offered at some centres but is associated with greater toxicity.

Bevacizumab (Anti-VEGF): Addition of bevacizumab 15 mg/kg every 3 weeks to first-line chemotherapy and continued as maintenance prolongs PFS by ~4 months (GOG-218: PFS 14.1 vs 10.3 months; ICON7: PFS 19.0 vs 17.3 months). OS benefit is most significant in high-risk patients (stage IV or inoperable stage III). Bevacizumab + olaparib maintenance (PAOLA-1) showed PFS 22.1 vs 16.6 months overall, with greatest benefit in HRD-positive/BRCA-mutated tumours.

PARP Inhibitor Maintenance: Olaparib 300 mg twice daily (SOLO-1: PFS HR 0.30 in BRCA1/2-mutated patients in first-line CR/PR; 5-year data: PFS 48.3% vs 20.6%). Niraparib 200–300 mg daily (PRIMA: overall PFS HR 0.62; HRD-positive patients: PFS 13.8 vs 8.2 months; BRCAmut patients: PFS 22.1 vs 10.9 months). Rucaparib (ARIEL3: PFS benefit in all three biomarker cohorts — BRCAmut, HRD, intent-to-treat). All three agents are approved for first-line maintenance in appropriate patient populations following carboplatin-based chemotherapy.

The combination of optimal surgery with modern targeted maintenance therapy has transformed outcomes for patients with advanced ovarian cancer, particularly in BRCA-mutated and HRD-positive disease:

• Complete cytoreduction (R0) benefit: Meta-analyses consistently demonstrate that each 10% increase in the proportion of patients achieving R0 correlates with a 5.5% improvement in median OS. Patients achieving R0 at primary debulking have median OS of 50–60 months vs 20–30 months for those with residual disease >1 cm (du Bois et al., Gynecol Oncol 2009).
• Olaparib (SOLO-1, BRCA-mutated first-line maintenance): At 5-year follow-up, 48.3% of olaparib patients vs 20.6% of placebo patients remained progression-free (HR 0.33). Updated OS HR at 7 years: 0.55, with 67% of olaparib patients alive at 5 years vs 46% on placebo — a transformational result in BRCA-mutated advanced EOC.
• Niraparib (PRIMA, HRD-positive population): In HRD-positive patients (BRCA-mutated or BRCA wild-type with HRD-positive genomic scar), median PFS 13.8 vs 8.2 months (HR 0.43); in BRCA-mutated subgroup, PFS 22.1 vs 10.9 months. Niraparib is weight/platelet-adjusted for individualised starting dosing.
• HIPEC (van Driel, NEJM 2018): HIPEC with cisplatin at IDS improved median OS from 33.9 to 45.7 months (HR 0.67; 95% CI 0.48–0.94; P=0.02) in a randomised trial. This represents a 12-month OS gain from a single surgical procedure component.
• Bevacizumab (ICON7, high-risk patients): In high-risk stage IV or inoperable stage III patients, bevacizumab added to chemotherapy and continued as maintenance improved OS by 9.4 months (28.8 vs 19.4 months, HR 0.64).
• Early detection of hereditary risk: BRCA germline testing identifies women at 40–60% lifetime risk of ovarian cancer; risk-reducing salpingo-oophorectomy reduces ovarian cancer risk by ~90% and overall mortality in BRCA carriers.

Treatment for ovarian cancer involves risks from extensive surgery, platinum-based chemotherapy, anti-angiogenic agents, and PARP inhibitors. Understanding and proactively managing these risks is central to optimal outcomes:

Surgical Complications: Extended debulking operations carry significant risks: blood loss requiring transfusion (~30–50%), bowel resection complications (anastomotic leak ~3–5%), wound infection, venous thromboembolism (DVT/PE — prophylaxis with LMWH is mandatory), bladder or ureteric injury (<2%), and prolonged ileus. Hospital stay is typically 7–10 days following major debulking. Mortality from primary debulking in specialist centres is <1–2%. HIPEC adds ~2 hours of operative time and cisplatin-associated nephrotoxicity risk (aggressive IV hydration required).

Carboplatin + Paclitaxel Toxicity: Carboplatin causes thrombocytopenia (dose-limiting), anaemia, nausea, and, rarely, hypersensitivity reactions (increasing with re-exposure). Paclitaxel causes peripheral sensory neuropathy (cumulative; grade 3 in ~5–8%), alopecia, and arthralgia/myalgia. Hypersensitivity reactions to paclitaxel (especially solvent-based formulations) require pre-medication with dexamethasone, antihistamine, and H2 blocker. Carboplatin hypersensitivity develops in ~10–27% of heavily re-treated patients and can be managed with desensitisation protocols.

Bevacizumab Toxicity: Hypertension (grade 3 ~18% requiring antihypertensive medication), proteinuria (grade ≥2 ~8%), delayed wound healing (bevacizumab must be withheld ≥28 days before and after surgery), arterial thromboembolic events (stroke/MI, ~1–3%), bowel perforation (particularly in heavily pre-treated patients with peritoneal disease, ~1%). Bevacizumab is contraindicated in the presence of haemoptysis, poorly controlled hypertension, or recent arterial thromboembolism.

PARP Inhibitor Toxicity: Nausea and fatigue are common (any grade ~70%); anaemia (grade 3/4: ~25% olaparib, ~31% niraparib), thrombocytopenia (grade 3/4: ~3% olaparib, ~29% niraparib requiring weight/platelet-adjusted starting dose). Risk of MDS/AML is ~1–2% with prolonged exposure, particularly in heavily pre-treated patients or those with prior alkylating agent exposure. Monthly full blood count monitoring for the first year is mandatory across all agents.

Fertility Considerations: Standard treatment (bilateral salpingo-oophorectomy + chemotherapy) results in surgical menopause and permanent infertility in pre-menopausal women. For early-stage germ cell or borderline tumours in young women, fertility-sparing surgery (unilateral oophorectomy) may be appropriate with MDT review. Oocyte/embryo cryopreservation should be offered before chemotherapy where time allows.

After completion of first-line treatment, structured surveillance is recommended to detect recurrence early and monitor for maintenance therapy toxicity. ESMO/ESGO 2022 ovarian cancer guidelines and NCCN 2024 provide the following framework:

Surveillance Schedule: Clinical review every 3 months for the first 2 years, then every 6 months for years 3–5, then annually. Each visit includes history and examination; CA-125 at every visit where measurable at baseline (a ≥2-fold rise above ULN is clinically significant). CT chest/abdomen/pelvis is indicated when symptoms or CA-125 suggest recurrence — routine CT surveillance in asymptomatic patients is not recommended in ESMO guidelines but is practised at many centres.

CA-125 in Surveillance: The MRC OV05/EORTC 55955 trial demonstrated that early initiation of chemotherapy based on CA-125 rise alone (before clinical/radiological recurrence) did not improve OS and reduced quality of life. ESMO recommends informing patients of this finding; many clinicians continue CA-125 monitoring for patient reassurance and readiness planning.

PARP Inhibitor Maintenance Monitoring:

• Full blood count: monthly for first year, then every 3 months
• Renal function and LFTs: every 3 months during maintenance
• For olaparib: MDS/AML screen (FBC differential, consider bone marrow biopsy) if unexplained cytopaenia persists >4 weeks
• Blood pressure monitoring: monthly during bevacizumab maintenance

Recurrence Treatment: Relapse is categorised by platinum-free interval (PFI). Platinum-sensitive relapse (PFI >6 months): re-challenge with carboplatin-based combination (ICON4: carboplatin + paclitaxel; AGO-OVAR 2.5: gemcitabine + carboplatin; CALYPSO: carboplatin + pegylated liposomal doxorubicin). Following response, PARP inhibitor maintenance in second-line setting (STUDY 19/SOLO-2 for olaparib; ARIEL3 for rucaparib). Platinum-resistant relapse (PFI <6 months): pegylated liposomal doxorubicin (Caelyx/Doxil), gemcitabine, weekly paclitaxel, or topotecan ± bevacizumab (AURELIA trial: PFS 6.7 vs 3.4 months).

Genetic Counselling: All patients with identified germline BRCA1/2 or other hereditary cancer syndrome mutations should be referred for genetic counselling and offered cascade testing to first-degree relatives. Prophylactic risk-reducing salpingo-oophorectomy recommendations for at-risk relatives should be communicated clearly.

Ovarian cancer treatment involves substantial costs across surgery, chemotherapy, maintenance targeted therapy, and genetic testing. Access varies significantly by country and healthcare system:

Surgical Costs: Primary debulking surgery at a specialist gynaecological oncology centre in the US costs approximately USD 30,000–80,000 (hospital and professional fees combined). HIPEC adds approximately USD 15,000–25,000 to the surgical episode. In India, comparable quality surgery at NABH-accredited cancer centres costs USD 3,000–10,000. UK NHS provides all surgery at no direct patient cost.

Chemotherapy Costs (per 6-cycle course): Carboplatin + paclitaxel: USD 8,000–20,000 in the US; approximately USD 1,000–3,000 in India using generic formulations. Bevacizumab (Avastin) adds approximately USD 18,000–25,000 per year; biosimilars (bevacizumab-awwb, Zirabev) reduce costs by 15–30% in the US; generic bevacizumab is available in India.

PARP Inhibitor Costs (annual maintenance):

• Olaparib (Lynparza): ~USD 170,000–185,000/year in the US; ~USD 15,000–25,000/year in India (generic olaparib available)
• Niraparib (Zejula): ~USD 175,000/year in the US; GlaxoSmithKline My Support360 programme provides patient assistance
• Rucaparib (Rubraca): US availability limited after Clovis Oncology bankruptcy; generic versions available internationally

Genetic Testing Costs: BRCA germline testing (Myriad BRACAnalysis) ~USD 250–4,000 depending on US insurance coverage; most payers cover testing given its direct clinical utility. Myriad myChoice CDx HRD testing: ~USD 3,500–4,500. In India, germline BRCA testing costs approximately USD 200–500.

NHS Coverage (UK): Olaparib has NICE Technology Appraisal approval for BRCA-mutated EOC; niraparib is NICE-approved for HRD-positive patients. All first-line chemotherapy and carboplatin-sensitive relapse regimens are fully NHS-funded. Bevacizumab has conditional NHS approval.

Medical Tourism: India, Thailand, and Turkey offer high-quality ovarian cancer treatment at 30–60% lower total costs than Western markets, with NABH/JCI-accredited gynaecological oncology programmes at major cancer centres in Mumbai, Delhi, Chennai, Bangkok, and Istanbul.

The treatment landscape for ovarian cancer continues to evolve rapidly. Several emerging therapeutic strategies and complementary approaches are available beyond standard first-line care:

Clinical Trials and Emerging Agents: Mirvetuximab soravtansine (FORWARD I, MIRASOL) is an ADC targeting folate receptor alpha (FRα), approved by FDA for FRα-positive platinum-resistant ovarian cancer following the MIRASOL trial (OS 16.5 vs 12.8 months vs chemotherapy). Immune checkpoint inhibitors have shown limited activity in unselected platinum-resistant ovarian cancer; pembrolizumab may have activity in TMB-high or MSI-high tumours. PARP inhibitor + CDK4/6 inhibitor combinations (olaparib + capivasertib) and PARP + VEGF combinations beyond olaparib + bevacizumab are in active evaluation. Atezolizumab + bevacizumab + carboplatin/paclitaxel (IMagyn050) did not improve PFS in an unselected population but may benefit PD-L1-positive subgroups.

Intraperitoneal (IP) Chemotherapy: Historically (GOG-172: IP cisplatin + paclitaxel + IV paclitaxel vs IV cisplatin + paclitaxel; OS 65.6 vs 49.7 months), IP chemotherapy showed significant OS benefit but high toxicity rates prevented widespread adoption. The GOG-252 trial compared IV carboplatin + bevacizumab vs IP cisplatin + IV paclitaxel + bevacizumab: PFS was similar between arms, and IP cisplatin was not superior. Current ESMO guidelines do not recommend routine IP chemotherapy outside clinical trials. HIPEC (at the time of surgery) remains the preferred intraperitoneal approach.

MEK Inhibitors for Low-Grade Serous Carcinoma: Trametinib (MEK inhibitor) showed ORR 26% vs 6% for physician-choice chemotherapy in the GOG-281/LOGS trial in relapsed LGSC (PFS 13.0 vs 7.2 months; HR 0.48). Trametinib represents an important alternative for LGSC, which is relatively chemotherapy-resistant.

Integrative Oncology: Evidence-based supportive therapies — acupuncture for chemotherapy-induced nausea and peripheral neuropathy, ginger supplementation for nausea, cognitive behavioural therapy for cancer-related anxiety — are recommended as adjuncts to standard care per ASCO integrative oncology guidelines (2023). Supervised exercise during treatment reduces fatigue and improves quality of life.

Palliative and Supportive Care: Early specialist palliative care integration from diagnosis of advanced ovarian cancer improves quality of life and symptom burden. Ascites management (repeated paracentesis, peritoneovenous shunting, intracavitary bevacizumab off-label), bowel obstruction palliation (TPN, stenting, surgical bypass where appropriate), and goals-of-care planning are core components of a comprehensive, patient-centred ovarian cancer programme.